Attention to Immortal Time Bias in Critical Care Research

被引:26
|
作者
Vail, Emily A. [1 ,2 ]
Gershengorn, Hayley B. [3 ,4 ]
Wunsch, Hannah [5 ,6 ,7 ]
Walkey, Allan J. [8 ]
机构
[1] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA
[2] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA
[3] Univ Miami, Miller Sch Med, Div Pulm Crit Care & Sleep Med, Miami, FL 33136 USA
[4] Albert Einstein Coll Med, Div Crit Care Med, Bronx, NY 10467 USA
[5] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON, Canada
[6] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada
[7] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada
[8] Boston Univ, Sch Med, Dept Med, Div Pulm Allergy Sleep & Crit Care Med, Boston, MA 02118 USA
关键词
statistical bias; critical care medicine; comparative effectiveness research; OBSTRUCTIVE PULMONARY-DISEASE; SEPTIC SHOCK; VITAMIN-C; INHALED CORTICOSTEROIDS; CAUSAL INFERENCE; THIAMINE; OUTCOMES; THERAPY;
D O I
10.1164/rccm.202008-3238CP
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Observational studies in critical care medicine offer a popular and practical approach to questions of treatment effectiveness. Although observational research is widely understood to be susceptible to design and interpretation challenges, one well-described source of bias-immortal time bias (ITB)-is frequently present yet often overlooked. ITB may be introduced by study design oversights or mishandled during data analysis. When present, ITB can create inappropriate estimates of the benefit or harm of an exposure or intervention. Studies examining treatments in critically ill patients may be particularly susceptible to ITB, with consequences for clinical adoption and design and initiation of randomized trials. In this Critical Care Perspective, we illustrate the persistent problem of ITB in observational research using recent studies of hydrocortisone, ascorbic acid, and thiamine therapy in patients with sepsis and septic shock. Of the eight studies examined, none contained enough design or reporting elements to rule out the presence of ITB. To mitigate the influence of ITB in future observational studies, we present a novel checklist to help readers assess the features of study design, analysis, and reporting that introduce ITB or obscure its presence. We recommend that commonly used tools designed to evaluate observational research studies should include an ITB assessment.
引用
收藏
页码:1222 / 1229
页数:8
相关论文
共 50 条
  • [41] Immortal Time Bias in the Analysis of Time-to-Event Data in Orthopedics
    Larson, Dirk R.
    Crowson, Cynthia S.
    Devick, Katrina L.
    Lewallen, David G.
    Berry, Daniel J.
    Kremers, Hilal Maradit
    JOURNAL OF ARTHROPLASTY, 2021, 36 (10): : 3372 - 3377
  • [42] Immortal Time Bias in Assessing Evidence-Based Care Processes for Staphylococcus aureus Bacteremia Reply
    Goto, Michihiko
    Perencevich, Eli N.
    Ohl, Michael E.
    JAMA INTERNAL MEDICINE, 2018, 178 (02) : 296 - 296
  • [43] Reply to: Immortal time bias in the analysis of drug prescription trajectories
    Laust Hvas Mortensen
    Søren Brunak
    npj Digital Medicine, 5
  • [44] Immortal Time Bias or Sorafenib Effect in Elderly Patients With HCC?
    Sanoff, Hanna K.
    Chang, YunKyung
    Lund, Jennifer L.
    O'Neil, Bert H.
    Dusetzina, Stacie B.
    HEPATOLOGY, 2017, 66 (02) : 678 - 679
  • [45] Reply to: Immortal time bias in an observational study on enteral nutrition
    Gutierrez, Alejandra
    Bartos, Jason A.
    RESUSCITATION, 2021, 166 : 146 - 147
  • [46] Immortal Time Bias in Cohort Studies of Kidney Transplant Recipients
    Kim, S. J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (01) : 190 - 190
  • [47] Geriatrician assessment and immortal time bias in the FiTR 2 study
    Cliff, Edward R. Scheffer
    T Denholm, Justin
    LANCET HEALTHY LONGEVITY, 2022, 3 (11): : E734 - E734
  • [48] Immortal Time Bias for Infliximab in Central Nervous System Tuberculosis
    Khan, Adil Rashid
    Tirlangi, Praveen Kumar
    Wig, Naveet
    Soneja, Manish
    CLINICAL INFECTIOUS DISEASES, 2024, 78 (02) : 491 - 491
  • [49] A NOVEL APPROACH FOR MINIMIZING IMMORTAL TIME BIAS IN OBSERVATIONAL STUDIES
    Kiri, V
    Messina, P.
    Knight, T.
    VALUE IN HEALTH, 2022, 25 (12) : S350 - S350
  • [50] Statins in Multiple Myeloma: Survival Benefit or Immortal Time Bias?
    Suissa, Samy
    Klil-Drori, Adi J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (12) : 1377 - +